Strongbridge Biopharma is a biopharmaceutical company focused on the development and commercialization of therapies for rare diseases. Co.'s commercial product is Keveyis® (dichlorphenamide), the treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis, a group of rare hereditary neuromuscular disorders that cause episodes of muscle weakness or paralysis. Co.'s clinical-stage product candidates are Recorlev, which is a cortisol synthesis inhibitor for the treatment of endogenous Cushing's syndrome; and veldoreotide, which is a somatostatin analog for potential applications in conditions amenable to somatostatin receptor activation. We show 17 historical shares outstanding datapoints in our SBBP shares outstanding history coverage, used to compute SBBP market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing SBBP market cap history over the course of time is important for investors
interested in comparing SBBP's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of SBBP versus a peer is one thing; comparing
SBBP market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like SBBP can fluctuate over the course of history.
With this page we aim to empower investors researching SBBP by allowing them to research the SBBP market cap history. |
Free SBBP Email Alerts:
Video: The Importance of Market Cap
